bluebird bio, Inc.

Good morning, ladies and gentlemen. Thank you for standing by. Welcome to Bluebird's BIOS third quarter 2024 results conference call. At this time, all participants are on a listen-only mode. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 1 on your telephone. You will then hear an automatic message advising your hand is raised. Please note that today's conference is being recorded. I'll now hand the conference over to your host, Courtney O'Leary, Director of Investor Relations. Please go ahead.

Good morning, everyone, and thank you for joining our third quarter 2024 results call today. My name is Courtney O'Leary, Director of Investor Relations at Bluebird Bio. Before we begin, let me review our safe harbor statement. Today's discussion contains statements that are forward-looking under the Private Securities Litigation Reform Act of 1995. including expectations regarding our future financial results and financial position, in addition to statements of the company's plans, expectations, or intentions regarding regulatory progress, commercialization plans, and business operations. Such statements are based on current expectations and assumptions that are subject to risks and uncertainties and involve a number of risk factors that could cause actual results to differ materially from projected results. A description of these risks is contained in our filings with the SEC. which are available on the investor relations section of our website, www.bluebirdbio.com. With that, I will turn it over to Bluebird Bio CEO, Andrew Obenshade.

Thank you, Courtney, and thank you, everyone, for joining our call this morning. As a gene therapy pioneer and the only standalone commercial-stage gene therapy company on the market today, we have built what we believe to be an unparalleled foundation over the past two years since our first FDA approval. With a robust, qualified treatment center network, proven access and reimbursement, and demonstrated demand for our therapies for both patients and from providers. Today, we are seeing the results of those efforts. Since we reported our Q2 earnings in August, we have more than doubled patient starts from 27 to 57 across our portfolio. We initiated steps to reduce our cash operating expenses by 20% in Q3 2025, and we've laid out a roadmap to financial stability and cash flow breakeven in the second half of next year. should we accomplish our goal of securing additional cash resources. On today's call, Tom Klima, Chief Commercial and Operating Officer, will provide updates on the commercial launches of Virginia, Centeglo, and Skysona. Then Bluebird CFO James Sterling will provide an update and some comments on our recent proxy vote before opening the call for Q&A.